Showing results (91-100 of 201) with videos related to

Sort By:
Pageof 21
Science (New York, N.Y.)|December 4, 1998
53Mn-53Cr dating of fayalite formation in the CV3 chondrite Mokoia: evidence for asteroidal alterationI D Hutcheon, A N Krot, K Keil, et al.
American Heart Journal|February 1, 1997
Presyncopal sympathetic withdrawal is the same in patients with vasodepressor syncope and controls who faint on head-up tiltingM Prinz-Zaiss, A N Yeap, V Moguilevski, et al.
Clinical and Experimental Pharmacology & Physiology|June 1, 1995
Power spectral analysis of heart rate variability during graded head-up tilting in patients with vasodepressor syncopeM Prinz-Zaiss, A N Yeap, V Moguilevski, et al.
Immunology|September 27, 2003
Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharideDeborah M Prinz, S Louise Smithson, Thomas Kieber-Emmons, et al.
Dermatology (Basel, Switzerland)|May 1, 2004
Subcutaneous infection with Mycobacterium abscessus in a renal transplant recipientB M Prinz, S Michaelis, N Kettelhack, et al.
Circulation|May 1, 1993
Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysisM Zabel, S H Hohnloser, W Köster, et al.
Science (New York, N.Y.)|January 3, 2009
Nanodiamonds in the Younger Dryas boundary sediment layerD J Kennett, J P Kennett, A West, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.
Clinical Pharmacology in Drug Development|May 4, 2022
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer ApproachRavi Shankar P Singh, Martin E Dowty, Mikhail Salganik, et al.
Clinical and Experimental Rheumatology|March 12, 2016
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritisJennifer A Hodge, Thomas T Kawabata, Sriram Krishnaswami, et al.
Pageof 21